BISTOS Co., Ltd.
KKRX:4195402,625.00
KRW
-35.00
(-1.32%)
ISIN
KR7419540000
Return %
Stock
S&P 500
1Y
-60.44
14.39
3Y
-73.82
81.42
5Y
- -
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Hoo-Jung Lee
- Full Time Employees
- 77
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Seongnam-si South Korea
- IPO Date
- Oct 18, 2022
- Website
- bistos.co.kr
- Similar Companies
- Business
- BISTOS Co., Ltd. is a South Korea-based medical device manufacturer specializing in the research, development, production, and global commercialization of bio-signal diagnostic, monitoring, and therapeutic equipment. Founded in 2001 and headquartered in Gwacheon-si, Gyeonggi-do, South Korea, with manufacturing facilities in Yongin-si and an overseas branch in Laguna Hills, California, the company derives the majority of its revenue from international export markets spanning more than 110 countries across North America, Europe, the Asia-Pacific region, Latin America, and the Middle East. BISTOS Co., Ltd. serves a diverse medical customer base comprising general hospitals, obstetrics and gynecology clinics, neonatal intensive care units, pediatric wards, and home healthcare consumers. The company organizes its offerings into several core product categories, comprising fetal and maternal monitoring systems, including ultrasound fetal dopplers (BT-200 and BT-220 series) and multi-channel antepartum and intrapartum fetal monitors (BT-300, BT-350, and BT-380 series); neonatal care and life-support equipment, including closed infant incubators (BT-500 and BT-550 series), infant radiant warmers (BT-500W), and neonatal jaundice phototherapy units (BT-400); general patient monitoring solutions, including multi-parameter vital signs monitors (BT-710, BT-720, BT-740, BT-750, and BT-770 series); therapeutic and neuro-stimulation devices, including transcutaneous electrical nerve stimulators for attention deficit hyperactivity disorder treatment (BT-1000) and electric breast pumps (BT-100 and BT-150B); and specialized clinical instruments, including non-contact infrared thermometers (BT-35), LED medical examination headlamps (BT-410), infusion pumps, and digital radiography X-ray imaging systems. In recent major developments, BISTOS Co., Ltd. completed its public listing on the KOSDAQ market (KRX: 419540) through a merger with SK No. 5 Special Purpose Acquisition Company. The company has since accelerated its strategic expansion into artificial intelligence-powered digital healthcare, advancing the commercial development of AI-integrated smart infant incubators, IoT-connected remote fetal monitoring systems, and non-invasive digital neurological therapies. In addition, BISTOS Co., Ltd. has expanded its production capacity, secured operational financing through private convertible bond issuances, implemented share repurchase programs to enhance shareholder value, and extended its global distribution channels across key international healthcare markets.